NCI SBIR Grant - T Cell Function Study

About LASE Innovation

LASE Innovation is an early-stage, private company based in Cambridge, MA, founded in 2019. It has developed a patented laser particle (LP™) technology for optical cell barcoding, allowing researchers to track hundreds of thousands to millions of individual cells over time and across different experimental modalities. The company operates primarily as a platform tools provider, with its first commercial service launched in collaboration with Talon Biomarkers in 2025. It has secured non-dilutive funding through SBIR grants from the National Cancer Institute (NCI) and is focused on enabling next-generation single-cell analysis for drug discovery and biomarker development.

Therapeutic Areas